← The SEC Ephemeris: the whole map
Cadence Pharmaceuticals Ofirmev
In the graph: all 1 documents (2 pages).
- Application
- NDA 022450
- Ticker
- Cadence Pharmaceuticals
- Product
- Ofirmev
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- February 10, 2010
From FDA letters and SEC filings. Not investment or medical advice.